Uncover what could happen with Humira and the biosimilar market in 2023
While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market.
Will biosimilar competitors increase competition, lower drug costs and knock Humira out of the top spot? It’s the top question our clinical pharmacists and industry experts are being asked to comment on. We’re sharing all the facts—and some of our own predictions—in our upcoming webinar.
Join us to learn:
How Humira dominated the autoimmune market
The Humira biosimilar competition
Our predictions for 2023 and beyond
Recommended next steps for industry stakeholders
If you’re a health plan, employer group, biosimilar manufacturer, PBM, broker, TPA, or a patient—you won’t want to miss it.
